RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
NCT07445022
·
clinicaltrials.gov ↗
PHASE4
Phase
RECRUITING
Status
110
Enrollment
OTHER
Sponsor class
Conditions
Melanoma Advanced
Interventions
DRUG:
tunlametinib
Sponsor
Fudan University